Literature DB >> 29171817

HIV Prevention Efforts and Incidence of HIV in Uganda.

M Kate Grabowski1, David M Serwadda1, Ronald H Gray1, Gertrude Nakigozi1, Godfrey Kigozi1, Joseph Kagaayi1, Robert Ssekubugu1, Fred Nalugoda1, Justin Lessler1, Thomas Lutalo1, Ronald M Galiwango1, Fred Makumbi1, Xiangrong Kong1, Donna Kabatesi1, Stella T Alamo1, Steven Wiersma1, Nelson K Sewankambo1, Aaron A R Tobian1, Oliver Laeyendecker1, Thomas C Quinn1, Steven J Reynolds1, Maria J Wawer1, Larry W Chang1.   

Abstract

BACKGROUND: To assess the effect of a combination strategy for prevention of human immunodeficiency virus (HIV) on the incidence of HIV infection, we analyzed the association between the incidence of HIV and the scale-up of antiretroviral therapy (ART) and medical male circumcision in Rakai, Uganda. Changes in population-level viral-load suppression and sexual behaviors were also examined.
METHODS: Between 1999 and 2016, data were collected from 30 communities with the use of 12 surveys in the Rakai Community Cohort Study, an open, population-based cohort of persons 15 to 49 years of age. We assessed trends in the incidence of HIV on the basis of observed seroconversion data, participant-reported use of ART, participant-reported male circumcision, viral-load suppression, and sexual behaviors.
RESULTS: In total, 33,937 study participants contributed 103,011 person-visits. A total of 17,870 persons who were initially HIV-negative were followed for 94,427 person-years; among these persons, 931 seroconversions were observed. ART was introduced in 2004, and by 2016, ART coverage was 69% (72% among women vs. 61% among men, P<0.001). HIV viral-load suppression among all HIV-positive persons increased from 42% in 2009 to 75% by 2016 (P<0.001). Male circumcision coverage increased from 15% in 1999 to 59% by 2016 (P<0.001). The percentage of adolescents 15 to 19 years of age who reported never having initiated sex (i.e., delayed sexual debut) increased from 30% in 1999 to 55% in 2016 (P<0.001). By 2016, the mean incidence of HIV infection had declined by 42% relative to the period before 2006 (i.e., before the scale-up of the combination strategy for HIV prevention) - from 1.17 cases per 100 person-years to 0.66 cases per 100 person-years (adjusted incidence rate ratio, 0.58; 95% confidence interval [CI], 0.45 to 0.76); declines were greater among men (adjusted incidence rate ratio, 0.46; 95% CI, 0.29 to 0.73) than among women (adjusted incidence rate ratio, 0.68; 95% CI, 0.50 to 0.94).
CONCLUSIONS: In this longitudinal study, the incidence of HIV infection declined significantly with the scale-up of a combination strategy for HIV prevention, which provides empirical evidence that interventions for HIV prevention can have a population-level effect. However, additional efforts are needed to overcome disparities according to sex and to achieve greater reductions in the incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others.).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29171817      PMCID: PMC5627523          DOI: 10.1056/NEJMoa1702150

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


INTRODUCTION

Combination HIV prevention (CHP) is the concurrent implementation of multiple interventions to reduce HIV incidence.1 Most CHP packages include antiretroviral therapy (ART) and medical male circumcision (MC), along with provision of HIV testing and counseling, condom promotion, and other behavioral interventions.2 CHP scale-up has been an intense focus of global health over the past decade.3 Modeling studies indicate that high coverage of ART and MC could substantially reduce HIV incidence to low-endemic levels,4 5 and potentially even lead to its elimination.6 7 However, the effectiveness of CHP remains uncertain due to challenges in increasing CHP coverage and in accurately measuring changes in population-level HIV incidence.8 9 Demonstrating the population-level effectiveness of CHP is critical to understanding whether the current evidence98 based interventions are sufficient for HIV mitigation and to guide resource allocation. While prior research from South Africa has shown that increasing community ART coverage reduces individual-level HIV risk, population-level HIV incidence declines were not demonstrated.10 11 Other research from North America suggests that ART scale-up has reduced HIV incidence, but these studies relied on modeled incidence and sentinel surveillance data.9 12-14 The “gold standard” for assessing HIV incidence is the longitudinal measurement of HIV seroconversions in a population-based cohort.8 9 However, these studies are rare despite the urgency to demonstrate relationships between changes in CHP coverage and HIV incidence over time.4 5 15 To assess the impact of CHP on HIV incidence, we analyzed long-term trends in HIV incidence based on observed seroconversions and their associations with ART and MC scale-up, population-level viral load suppression, and sexual behaviors in Rakai, Uganda.

METHODS

Cohort Description

The Rakai Community Cohort Study (RCCS), conducted by the Rakai Health Sciences Program (RHSP), is an open, population-based, multi-community cohort of individuals aged 15-49 years.16 The RCCS is situated in Rakai District (population ~518,000) which is mostly rural with scattered trading centers.17 This study uses data from thirty RCCS communities which were continuously surveyed from April 6, 1999 to September 2, 2016 over a total of twelve surveys (Supplemental Fig.1). To identify eligible participants, a household census enumerates all persons by gender, age, and duration of residence, regardless of whether they are present or currently absent. After the census, the RCCS surveys all present, age-eligible residents providing written informed consent. Participants are interviewed to assess demographics, sexual behaviors, ART use, and MC status. Venous blood is obtained for HIV testing at each survey (Supplemental RCCS laboratory methods). Funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR),18 CHP scale-up began in earnest in the mid-2000’s (Supplemental CHP scale-up).

Statistical Analysis

CHP coverage was assessed using person-visit data at each survey with descriptive statistics and logistic regression. Specifically, ART coverage was defined as the proportion of all HIV positive participants who self-reported ART use, regardless of ART eligibility criteria, and was assessed overall and separately by gender. Self-reported ART use in the cohort has been validated previously by plasma detection of antiretroviral drugs showing a specificity and sensitivity of 99% (95%CI: 97-100%) and 77% (95%CI: 70-83%), respectively, with no differences by gender.19 MC coverage at a given visit was defined as the proportion of men who self-reported being circumcised. Self-reported circumcision status has been previously validated from clinical records with 100% specificity.20 Viral suppression was defined using a cutoff of 1000 copies/ml as per WHO recommendations.21 The unit of exposure for HIV incidence were person-intervals of follow-up between surveys in initially HIV-negative individuals who participated in at least two surveys. HIV incident cases were persons who tested HIV-seropositive for the first time with an HIV seronegative test result at the prior RCCS visit, allowing for up to one missed visit. Incident infections were assumed to occur at the mid-point of the interval and changes in HIV incidence per 100 person years (py) were estimated using Poisson multivariate regression with generalized estimating equations and an exchangeable correlation structure and were reported as incidence rate ratios (IRR) with 95% confidence intervals (CI). To assess the impact of CHP, mean incidence at each visit interval after 2004 (6th survey) was compared to mean HIV incidence over the entire period prior to ART and MC availability. The final multivariate model included individual-level information on demographics (gender, age, marital status, education) and sexual behaviors (sexual partners in the last year, sex with partners outside the community of residence, sex with non-marital partners, condom use and self-reported genital ulceration). A categorical term for community-level HIV prevalence was included to adjust for variation in exposure. Secondary analyses were stratified by gender and conducted separately for circumcised and uncircumcised men. HIV incidence and individual risk was also assessed in relation to community-level measures of ART and MC coverage and prevalence of HIV viremia (Supplemental statistical methods). Sensitivity of results to both selective participation and loss to follow-up were evaluated using inverse probability weights (Supplemental statistical methods). To assess the potential impact of birth cohort effects on HIV incidence trends, a term for each five-year birth cohort was included in the multivariate model. HIV incidence was also assessed by gender for each five year age group.

RESULTS

Survey participation

Table 1 shows eligibility and participation summary statistics for the twelve surveys. Overall, 33,937 individual participants contributed 103,011 person-visits, including an incidence cohort of 17,870 initially HIV-negative persons followed for 94,427 person-years. The mean participation rate among all eligible persons censused was 64% and did not vary substantially between surveys (range: 59%-67%); however, reasons for non-participation and study drop-out (e.g. refusal, travel) changed over time (Supplemental Tables.1a-c, 2a-c). The proportion of individuals who refused participation steadily declined from 21% to 0.5% over the analysis period, whereas the proportions absent due to work or school increased from 18% to 31%. The most common reasons for loss to follow-up were out-migration from study communities (ranging from 42-63% of losses) and travel for work or school (ranging from 25-33% of losses).
Table 1.

Summary of eligibility, participation and follow-up in the RCCS by survey round, 1999-2016

SurveyInterview DateCensus EligibleαEligible and present for surveyβPercent eligible who participated in surveyγPercent eligible and present who participated in surveyHIV-negative participants eligible for incidence cohort*Percent of eligible HIV-negative participants who outmigrated prior to the subsequent surveyIncidence cohortPercent of age-eligible HIV-negative participants followedPercent of age and resident eligible HIV-negative participants followed**Years since prior survey visit
Median (range)no.no.Percent (no.)Percentno.Percent (no.)no.PercentPercentmedian (IQR)
1Oct.1999 (Apr.1999-Feb.2000)9869812561% (5992)74%------
2Oct.2000 (Feb. 2000-Feb.2001)10448856764% (6732)79%518311% (546)376073%93%1.0 (1.0,1.0)
3Jan.2002 (Apr.2001-May.2002)11316917665% (7340)80%727723% (1677)454062%82%1.3 (1.1,1.3)
4Apr.2003 (Jul.2002-Aug.2003)11436860360% (6856)80%790527% (2167)455558%80%1.2 (1.2,1.3)
5Jul.2004 (Sep.2003-Nov.2004)11860843659% (7038)83%801428% (2206)469359%81%1.3 (1.2,1.3)
6Jan.2006 (Feb.2005-Jun.2006)12528913765% (8097)89%776828% (2159)486763%87%1.5 (1.4,1.6)
7Oct.2007 (Aug.2006-Jun.2008)13636913063% (8645)95%862430% (2585)500158%83%1.7 (1.6,1.8)
8Jul.2009 (Jun.2008-Dec.2009)13293900965% (8691)96%967930% (2952)561158%84%1.7 (1.6,1.8)
9Jan.2011 (Jan.2010-Jun.2011)14629994966% (9643)97%968630% (2894)574259%85%1.6 (1.6,1.6)
10Jun.2012 (Aug.2011-May.2013)160071084666% (10588)98%1030029% (3032)617660%85%1.6 (1.5,1.7)
11Jul.2014 (Jul.2013-Jan.2015)174771156665% (11379)98%1141934% (3875)627755%83%2.0 (1.9,2.1)
12Jan.2016 (Jan.2015-Sep.2016)180651230866% (12010)98%1290831% (4017)712255%80%1.6 (1.4,2.0)

Residents aged 15-19 in the census.

Eligible census population present at time of survey,

Eligible census population present and participated in survey.

Includes all age-eligible HIV-negative participants from prior survey and any HIV-negative participants from two surveys prior if participant was absent at the most recent survey.

Calculation excludes HIV-negative persons who out-migrated prior to survey.

Residents aged 15-19 in the census. Eligible census population present at time of survey, Eligible census population present and participated in survey. Includes all age-eligible HIV-negative participants from prior survey and any HIV-negative participants from two surveys prior if participant was absent at the most recent survey. Calculation excludes HIV-negative persons who out-migrated prior to survey.

HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence in each visit interval during combination HIV prevention (CHP) scale-up to mean HIV incidence in the entire period prior to scale-up.

IRR=Incidence Rate Ratio; adjIRR=Adjusted incidence rate ratio; Final adjusted model included age, gender (full cohort only), marital status, level of education, number of sexual partners in past year, sex with partners outside community, self-reported genital ulcer disease, condom use with casual partners, community residence type (trading, agrarian), and community HIV prevalence. Participation and follow-up rates were significantly lower among younger individuals, men, and persons living in trading centers, but these associations were stable over time. Individuals with high-risk sexual behaviors were somewhat more likely to be lost to follow-up but this was also constant over time. (Supplemental Figs.2-4). The population growth rate, calculated from the censused resident population irrespective of age, was 3.4% per year.

Temporal trends in sexual behaviors

Figure 1 shows age-specific sexual behaviors by survey for HIV-negative men and women. The most substantive changes in sexual behaviors were in adolescents aged 15-19, among whom the proportion self-reporting no initiation of sex increased from 30% in 1999 to 55% in 2016 (p<0.0001) overall, and from 35% (n=194/553) to 56% (n=679/1207) in men, and 28% (n=209/757) to 55% (n=646/1165) over the same time period (p<0.001 for both). Adolescent men who initiated sex were also significantly less likely to report multiple sexual partners in the last survey (40% in 1999 versus 19% in 2016, p<0.001). There were no substantial changes in female multiple partnerships. Overall ages, levels of self-reported condom use with casual partners remained largely unchanged (Figures 1E and 1F).
Figure 1.

Sexual Behaviors in the Rakai Community Cohort Study, 1999-2016.

Figure shows proportion of HIV-negative men and women by age-group and overall ages reporting the following sexual behaviors A-B) never initiating sex (i.e. delayed sexual debut), C-D) multiple sexual partnerships among sexually active persons, and E-F) consistent condom use among those reporting casual (i.e. non-marital) sexual partnerships. The most substantial changes in sexual behaviors occurred among adolescent men and women aged 15-19 years reporting never initiating sex and adolescent men reporting multiple partnerships.

Sexual Behaviors in the Rakai Community Cohort Study, 1999-2016.

Figure shows proportion of HIV-negative men and women by age-group and overall ages reporting the following sexual behaviors A-B) never initiating sex (i.e. delayed sexual debut), C-D) multiple sexual partnerships among sexually active persons, and E-F) consistent condom use among those reporting casual (i.e. non-marital) sexual partnerships. The most substantial changes in sexual behaviors occurred among adolescent men and women aged 15-19 years reporting never initiating sex and adolescent men reporting multiple partnerships.

Scale up of biomedical HIV interventions and changes in population HIV viral load

The scale-up of biomedical HIV prevention interventions is shown in Figure 2. Self-reported ART use among all HIV-positive persons increased from 12% in 2006 to 69% in 2016 (p<0.001). ART coverage was consistently higher among women (p<0.001); however, the proportional increase in coverage was similar in both genders. By 2016, 61% of HIV-positive men (n=285/465) and 72% (n=766/1060) of women self-reported ART use (Supplemental Table A). ART coverage was highest among older age groups in all surveys (Supplemental Fig.5).
Figure 2.

Scale-up of antiretroviral therapy, viral suppression in HIV-positive participants and male circumcision, 1999-2016.

2A shows scale-up of ART coverage measured by selfreport in men, women and all HIV-positive RCCS participants beginning in 2006. Figure 2B show the proportion of all HIV-positive persons by gender and overall virologically suppressed (<1000 HIV copies/ml) in 2009 and 2016. 2C shows scale-up of MC coverage in men irrespective of religion by HIV status and overall beginning in 2004. 2D shows community-level MC coverage vs. community-level ART coverage for all 30 communities at each survey during CHP scale-up. A smoothing-spline was fit to the smooth curve to assess trend. Scale-up of interventions occurred simultaneously and increased significantly in all communities.

Scale-up of antiretroviral therapy, viral suppression in HIV-positive participants and male circumcision, 1999-2016.

2A shows scale-up of ART coverage measured by selfreport in men, women and all HIV-positive RCCS participants beginning in 2006. Figure 2B show the proportion of all HIV-positive persons by gender and overall virologically suppressed (<1000 HIV copies/ml) in 2009 and 2016. 2C shows scale-up of MC coverage in men irrespective of religion by HIV status and overall beginning in 2004. 2D shows community-level MC coverage vs. community-level ART coverage for all 30 communities at each survey during CHP scale-up. A smoothing-spline was fit to the smooth curve to assess trend. Scale-up of interventions occurred simultaneously and increased significantly in all communities. HIV viral load assays were obtained for 96% (1115/1160) of HIV-positive participants in 2009 and for 99.9% (1525/1526) of HIV-positive participants in 2016. Viral load suppression (<1000 cps mL) among those self-reporting ART use was 94% (n=1228/1312) and did not differ by gender (p=0.382) or survey visit (p=0.525). HIV viral load suppression in all HIV-positive participants increased concomitant with increasing ART coverage. By 2016, 75% (n=1151/1526) of all HIV-positive persons, regardless of whether or not they reported ART use, were virally suppressed compared with 42% (n=464/1115) in 2009 (p<0.001) (Figure 2B). Population coverage of MC also significantly increased from 15% (n=374/2518) in 1999 to 59% (n=3177/5361) in 2016 among all men (p<0.001) (Figure 2C), and from 3.5% (n=77/2217) to 53% (n=2492/4666, p<0.001) among non-Muslim men who are not traditionally circumcised at birth. MC coverage increased among both HIV-positive and HIV-negative men with highest coverage in younger men (Supplemental Table 3B, Supplemental Fig.5). Scale-up of ART and MC occurred concurrently in all communities (Figure 2D) and by 2016 were high in all 30 RCCS communities: median community-level ART coverage was 70% (IQR: 61-75) and median community-level MC coverage was 61% (IQR:55-65%).

Changes in HIV incidence over time

Figure 3 shows HIV incidence in the whole population, women, men, and circumcised and uncircumcised men. HIV incidence remained stable prior to CHP scale-up and began to significantly decline in 2012 (Fig. 3, Supplementary Table.4a-e). In 2016, mean HIV incidence declined by 42% from 1.17 per 100 py prior to CHP to 0.66 per 100 py (IRR=0.56, 95%CI: 0.44- 0.72; adjIRR=0.58; 0.45-0.76). The same incidence trends were observed when restricting analyses to sexually active adults and individuals over the age of 20 years (Supplementary Tables.4,5).
Figure 3.

HIV incidence and prevalence trends in the Rakai Community Cohort Study, 1996-2016.

Trends in HIV incidence and prevalence over the analysis period among all initially HIV-negative men and women in the incidence cohort (3A), women only (3B), men only (3C), and in men by circumcision status (3D). HIV incidence is only shown for circumcised men ginning in 2007 after the WHO recommendation for MC for HIV-negative men for HIV prevention. HIV prevalence is shown in red and HIV incidence and 95% CI for each visit interval are shown in blue (green for circumcised men). The ART and MC coverage plots are also included to show the temporal association between scale-up of CHP and declines in HIV incidence.

HIV incidence and prevalence trends in the Rakai Community Cohort Study, 1996-2016.

Trends in HIV incidence and prevalence over the analysis period among all initially HIV-negative men and women in the incidence cohort (3A), women only (3B), men only (3C), and in men by circumcision status (3D). HIV incidence is only shown for circumcised men ginning in 2007 after the WHO recommendation for MC for HIV-negative men for HIV prevention. HIV prevalence is shown in red and HIV incidence and 95% CI for each visit interval are shown in blue (green for circumcised men). The ART and MC coverage plots are also included to show the temporal association between scale-up of CHP and declines in HIV incidence. Declines in incidence were greater in men (adjIRR=0.46; 95%CI: 0.29-0.73) than in women (adjIRR=0.68, 95%CI: 0.50-0.94). HIV incidence was lower in circumcised compared to uncircumcised men (adjIRR=0.61: 95%CI: 0.48-0.79), but incidence declined significantly in both circumcised men (adjIRR=0.43; 95%CI: 0.19-0.99) and uncircumcised men by 2016 (adjIRR: 0.51, 95%CI: 0.29-0.88) (Fig.3, Supplementary Tables.4b-e). There were HIV incidence declines among the majority of male and female age groups, and among both genders residing in trading and agrarian communities (Supplementary Fig.6-7). In sensitivity analyses, inclusion of birth cohort or inverse probability weights for selective participation and follow-up did not change inferences (Supplementary Tables 7-8). Though CHP coverage concurrently increased across RCCS communities (Fig. 2D., Supplemental Fig.7-8), we also assessed HIV incidence and individual-level HIV risk as functions of ART coverage, population prevalence of viremia, and MC coverage at the community-level. These analyses showed declining incidence and lower individual-level risk with increasing community ART and MC coverage and declining population viremia (Supplemental Fig.9-11).

DISCUSSION

In this study, HIV incidence significantly declined with CHP scale-up, providing some of the first empiric evidence that CHP can have substantial population-level impact. The declines in HIV incidence are likely due to ART and MC scale-up; reduced sexual activity in late adolescence may also have contributed. HIV incidence declined less in women compared to men, suggesting that the combined direct effects of MC and indirect effects of female ART use differentially benefited men. Additional efforts are needed to avert new infections in women such as further scale-up of ART in men and potentially introducing new primary prevention interventions (e.g. Pre-exposure Prophylaxis or PrEP). We previously found that community-levels of MC and female ART at modest coverage levels were associated with lower community HIV incidence in males.22 A study in rural South Africa reported lower risk of individual-level HIV acquisition associated with higher rates of ART coverage, but that study did not assess temporal declines in incidence or MC coverage.10 Our finding of a 42% reduction in HIV incidence to 0.66/100py is substantial, but still well above the 0.1/100py incidence rate estimated as the threshold for HIV elimination.6 23 From 2009 to 2016, the proportion of HIV-positive persons with viral suppression increased by 46%, suggesting that HIV viral suppression via ART likely reduced HIV exposure to uninfected opposite sex partners, consistent with other studies.12 13 24-26 By 2016, the rate of virologic suppression among HIV-positive persons was 75%, meeting the 2020 goal of the UNAIDS 90-90-90 initiative which modeling suggests could end the HIV epidemic by 2030.27 Our results demonstrate that ambitious ART scale-up goals can be achieved. Similar viral suppression results have been reported in Botswana (71%), although beneficial effects on HIV incidence rates in Botswana have not yet been reported.28 29 MC coverage steadily increased to 59% by 2016, but remained below UNAIDS targets of 80% coverage.30 Scale up of ART and MC were highly correlated (Fig. 2D) so it is difficult to disaggregate their effects. Nevertheless, we attempted to address this issue empirically by assessing HIV incidence trends separately in men and women and in uncircumcised and circumcised men. Prior mathematical modeling studies suggest that there are substantial, long term indirect effects of MC on both female partner HIV incidence and in uncircumcised men; however, these benefits are unlikely to be realized until at least a decade after HIV prevalence declines resulting from direct effects of MC.31 Therefore, the significant reductions of HIV incidence in women and uncircumcised men observed in this study most likely result from the population-level impact of increasing ART coverage on HIV incidence. Notably, circumcised men had the sharpest declines in HIV incidence, nearly twice as great as uncircumcised men, likely because they benefit from the direct protective effect of MC and from the indirect effect of female partners on ART. In comparison, women and uncircumcised men had more moderate declines in incidence, likely because they largely benefit from indirect reduced exposure afforded by their partner’s ART use. Rates of ART use were lower in HIV-positive men, which would further attenuate benefits for women.31 Statistically significant HIV incidence declines were first observed in 2012 when ART and MC coverage levels reached 36% and 43%, respectively. It would be tempting to conclude that these coverage levels represent threshold effects, but because interventions were scaled concurrently and the impact of interventions may be delayed, we cannot reliably make such inferences from these empiric data alone. Defining intervention thresholds would also depend on the proportion of infections introduced from outside the population of interest, a quantity which likely varies across settings. We found reductions in sexual activity in both males and females aged 15-19. Prior RHSP studies showed a decline in HIV incidence among 15-19 year-old girls associated with factors such as delayed sexual debut, coincident with increased school enrollment.32 However, this age group represents a small fraction of all incident HIV infections in the RCCS with limited behavioral changes in older age groups suggesting its impact on population HIV incidence are likely modest. Of note, there were no significant changes in condom use in any age group which is sobering given many years of condom promotion and provision. This observational study meets almost all of Hill’s criteria for causality including a strong temporal association between CHP scale-up and HIV incidence declines, a dose-response relationship (i.e., greater declines in HIV incidence with increasing CHP coverage), consistency with prior studies of ART and MC, and biological plausibility.33 However, the study has a number of limitations. ART and MC coverage, and sexual behaviors were self-reported and may be subject to social desirability and other biases. However, there are no clear indications that any biases changed over time, and self-reported ART has been validated with high specificity in this population.19 Viral load testing was conducted on stored sera which may be subject to RNA degradation over time, potentially resulting in overestimation of viral suppression in the earlier survey and an underestimation of the magnitude of viral suppression over time.34 While RCCS has relatively high participation rates compared to other African population-based cohorts, there was substantial mobility which reduced participation and follow-up.35 36 However, participation rates among those present in the community increased over time, and sensitivity analyses to assess potential selection bias did not change our inferences. An important consideration is whether these CHP coverage and HIV incidence results can be generalized. RCCS demographic and behavioral data are largely consistent with Demographic and Health Surveys in the region.37 RCCS is an open population-based cohort with extensive in and out-migration which likely minimized, though did not eliminate, potential Hawthorne effects of repeat observations. RHSP has conducted CHP intervention and prevention studies which may have increased ART and MC coverage.38-40 All RCCS participants are offered HIV testing services resulting in high coverage (98% in 2015). Although conditions in Rakai may have been favorable for rapidly scaling CHP services, the impact of these interventions on population-level HIV incidence provides proof of concept and should be generalizable. Indeed, data from the Uganda Ministry of Health’s National AIDS Control Program data indicates dramatic scale-up of CHP was also occurring nationally: ART and MC coverage were 68% and 54%, respectively, in 2016 (Steven Wiersma, personal communication, 2017). In summary, data from this longitudinal cohort in Rakai, Uganda show a 42% decline in HIV incidence associated with CHP, providing evidence that HIV control efforts can have a substantial population-level impact. Differential declines in HIV incidence by gender indicate a need for strengthening CHP efforts to benefit women, including improving ART coverage in men and consideration of newer, primary prevention interventions such as PrEP. Intensification of CHP efforts for both women and men including key underserved populations such as migrants, as well as long-term surveillance, are needed to determine whether HIV incidence can be further reduced to the levels necessary for elimination.
Table 2

HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence in each visit interval during combination HIV prevention (CHP) scale-up to mean HIV incidence in the entire period prior to scale-up.

IRR=Incidence Rate Ratio; adjIRR=Adjusted incidence rate ratio; Final adjusted model included age, gender (full cohort only), marital status, level of education, number of sexual partners in past year, sex with partners outside community, self-reported genital ulcer disease, condom use with casual partners, community residence type (trading, agrarian), and community HIV prevalence.

HIV incidence Cohort (N=17,780)
Survey(s)Incident HIV casesperson-yearsHIV incidence per 100 py (95%CI)IRR (95%CI)p-valueadjIRR (95% CI)p-value
Pre-CHP (2-5)254217651.17 (1.03,1.32)Ref.-Ref.-
Jan.2006 (6)8677731.11 (0.89,1.36)0.95 (0.74,1.21)0.660.94 (0.73,1.2)0.61
Oct.2007 (7)10587691.2 (0.98,1.44)1.02 (0.82,1.29)0.841.00 (0.79,1.26)0.99
Jul.2009 (8)125102011.23 (1.02,1.45)1.05 (0.85,1.3)0.670.95 (0.76,1.18)0.62
Jan.2011 (9)10598151.07 (0.88,1.29)0.91 (0.73,1.15)0.440.94 (0.74,1.19)0.60
Jun.2012 (10)86103520.83 (0.67,1.02)0.71 (0.55,0.91)0.0060.72 (0.56,0.93)0.012
Jul.2014 (11)87131590.66 (0.53,0.81)0.56 (0.44,0.72)<0.0010.60 (0.47,0.78)<0.001
Jan.2016 (12)83125930.66 (0.53,0.81)0.56 (0.44,0.72)<0.0010.58 (0.45,0.76)<0.001
  31 in total

1.  Effectiveness of peer support on care engagement and preventive care intervention utilization among pre-antiretroviral therapy, HIV-infected adults in Rakai, Uganda: a randomized trial.

Authors:  Larry W Chang; Gertrude Nakigozi; Veena G Billioux; Ronald H Gray; David Serwadda; Thomas C Quinn; Maria J Wawer; Robert C Bollinger; Steven J Reynolds
Journal:  AIDS Behav       Date:  2015-10

2.  High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.

Authors:  Frank Tanser; Till Bärnighausen; Erofili Grapsa; Jaffer Zaidi; Marie-Louise Newell
Journal:  Science       Date:  2013-02-22       Impact factor: 47.728

3.  Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda.

Authors:  Xiangrong Kong; Godfrey Kigozi; Joseph Ssekasanvu; Fred Nalugoda; Gertrude Nakigozi; Anthony Ndyanabo; Tom Lutalo; Steven J Reynolds; Robert Ssekubugu; Joseph Kagaayi; Eva Bugos; Larry W Chang; Pilgrim Nanlesta; Grabowski Mary; Amanda Berman; Thomas C Quinn; David Serwadda; Maria J Wawer; Ronald H Gray
Journal:  JAMA       Date:  2016-07-12       Impact factor: 56.272

4.  The accuracy of women's reports of their partner's male circumcision status in Rakai, Uganda.

Authors:  Xiangrong Kong; Anthony Ndyanabo; Fred Nalugoda; Godfrey Kigozi; Joseph Ssekasanvu; Tom Lutalo; David Serwadda; Maria Wawer; Ronald Gray
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

5.  Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men.

Authors:  Justin T Okano; Danielle Robbins; Laurence Palk; Jan Gerstoft; Niels Obel; Sally Blower
Journal:  Lancet Infect Dis       Date:  2016-05-09       Impact factor: 25.071

6.  Trends in HIV acquisition, risk factors and prevention policies among youth in Uganda, 1999-2011.

Authors:  John S Santelli; Zoe R Edelstein; Ying Wei; Sanyukta Mathur; Xiaoyu Song; Ashley Schuyler; Fred Nalugoda; Tom Lutalo; Ron Gray; Maria Wawer; David Serwadda
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

Review 7.  Combination HIV prevention: significance, challenges, and opportunities.

Authors:  Ann E Kurth; Connie Celum; Jared M Baeten; Sten H Vermund; Judith N Wasserheit
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

8.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

9.  Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.

Authors:  Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

10.  Participation dynamics in population-based longitudinal HIV surveillance in rural South Africa.

Authors:  Joseph Larmarange; Joël Mossong; Till Bärnighausen; Marie Louise Newell
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

View more
  82 in total

1.  Validation of the Limiting Antigen Avidity Assay to Estimate Level and Trends in HIV Incidence in an A/D Epidemic in Rakai, Uganda.

Authors:  Oliver Laeyendecker; Ronald H Gray; M Kate Grabowski; Steven J Reynolds; Anthony Ndyanabo; Joseph Ssekasanvu; Reinaldo E Fernandez; Maria J Wawer; David Serwadda; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2019-01-29       Impact factor: 2.205

2.  Epidemiology at a time for unity.

Authors:  Bryan Lau; Priya Duggal; Stephan Ehrhardt
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196

3.  Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study.

Authors:  Joseph Kagaayi; Larry W Chang; Victor Ssempijja; M Kate Grabowski; Robert Ssekubugu; Gertrude Nakigozi; Godfrey Kigozi; David M Serwadda; Ronald H Gray; Fred Nalugoda; Nelson K Sewankambo; Lisa Nelson; Lisa A Mills; Donna Kabatesi; Stella Alamo; Caitlin E Kennedy; Aaron A R Tobian; John S Santelli; Anna Mia Ekström; Helena Nordenstedt; Thomas C Quinn; Maria J Wawer; Steven J Reynolds
Journal:  Lancet HIV       Date:  2019-09-15       Impact factor: 12.767

4.  HIV-1 Subtype Distribution and Diversity Over 18 Years in Rakai, Uganda.

Authors:  Susanna L Lamers; Rebecca Rose; Sissy Cross; Christopher W Rodriguez; Andrew D Redd; Thomas C Quinn; David Serwadda; Joseph Kagaayi; Godfrey Kigozi; Ronald Galiwango; Ronald H Gray; M Kate Grabowski; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2020-06       Impact factor: 2.205

5.  Sexual risk behaviors following circumcision among HIV-positive men in Rakai, Uganda.

Authors:  Edward Nelson Kankaka; Joseph Ssekasanvu; Jessica Prodger; Dorean Nabukalu; Hadijja Nakawooya; Anthony Ndyanabo; Godfrey Kigozi; Ronald Gray
Journal:  AIDS Care       Date:  2018-02-13

6.  Trends Over Time for Adolescents Enrolling in HIV Care in Kenya, Tanzania, and Uganda From 2001-2014.

Authors:  Edith Apondi; John M Humphrey; Edwin Sang; Ann Mwangi; Alfred Keter; Beverly S Musick; Fred K Nalugoda; John Ssali; Elizabeth Bukusi; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Samuel Ayaya
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

7.  Narrating the Transition to Adulthood for Youth in Uganda: Leaving School, Mobility, Risky Occupations, and HIV.

Authors:  Philip Kreniske; Stephanie Grilo; Neema Nakyanjo; Fred Nalugoda; Jason Wolfe; John S Santelli
Journal:  Health Educ Behav       Date:  2019-02-21

8.  HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.

Authors:  Diane V Havlir; Laura B Balzer; Edwin D Charlebois; Tamara D Clark; Dalsone Kwarisiima; James Ayieko; Jane Kabami; Norton Sang; Teri Liegler; Gabriel Chamie; Carol S Camlin; Vivek Jain; Kevin Kadede; Mucunguzi Atukunda; Theodore Ruel; Starley B Shade; Emmanuel Ssemmondo; Dathan M Byonanebye; Florence Mwangwa; Asiphas Owaraganise; Winter Olilo; Douglas Black; Katherine Snyman; Rachel Burger; Monica Getahun; Jackson Achando; Benard Awuonda; Hellen Nakato; Joel Kironde; Samuel Okiror; Harsha Thirumurthy; Catherine Koss; Lillian Brown; Carina Marquez; Joshua Schwab; Geoff Lavoy; Albert Plenty; Erick Mugoma Wafula; Patrick Omanya; Yea-Hung Chen; James F Rooney; Melanie Bacon; Mark van der Laan; Craig R Cohen; Elizabeth Bukusi; Moses R Kamya; Maya Petersen
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 91.245

Review 9.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Authors:  Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

10.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.